AI Verdict
RARE has stronger fundamentals based on our AI analysis.
RARE vs RAPH Fundamental Comparison
| Metric | RARE | RAPH |
|---|---|---|
| Revenue | $673.0M | N/A |
| Net Income | $-575.0M | $-1.3M |
| Net Margin | -85.4% | N/A |
| ROE | N/A | N/A |
| ROA | -37.5% | -2,413.2% |
| Current Ratio | 2.48x | 0.03x |
| Debt/Equity | N/A | N/A |
| EPS | $-5.83 | $0.07 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RARE vs RAPH: Frequently Asked Questions
Is RARE or RAPH a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RARE has stronger fundamentals. RARE is rated SELL (72% confidence) while RAPH is rated STRONG SELL (90% confidence). This is not investment advice.
How does RARE compare to RAPH fundamentally?
Ultragenyx Pharmaceutical Inc. has ROE of N/A vs Raphael Pharmaceutical Inc.'s N/A. Net margins are -85.4% vs N/A respectively.
Which stock pays higher dividends, RARE or RAPH?
RARE has a dividend yield of N/A or no dividend while RAPH has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RARE or RAPH for long term?
For long-term investing, consider that RARE has SELL rating with 72% confidence, while RAPH has STRONG SELL rating with 90% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RARE vs RAPH?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RARE vs RAPH, the AI consensus favors RARE based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.